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ABSTRACT
Developing a quantitative view of how biological
pathways are regulated in response to environmen-
tal factors is central for understanding of disease
phenotypes. We present a computational framework,
named Multivariate Inference of Pathway Activity
(MIPA), which quantifies degree of activity induced
in a biological pathway by computing five distinct
measures from transcriptomic profiles of its member
genes. Statistical significance of inferred activity is
examined using multiple independent self-contained
tests followed by a competitive analysis. The method
incorporates a new algorithm to identify a subset
of genes that may regulate the extent of activity in-
duced in a pathway. We present an in-depth evalu-
ation of specificity, robustness, and reproducibility
of our method. We benchmarked MIPA’s false posi-
tive rate at less than 1%. Using transcriptomic pro-
files representing distinct physiological and disease
states, we illustrate applicability of our method in
(i) identifying gene–gene interactions in autophagy-
dependent response to Salmonella infection, (ii) un-
covering gene–environment interactions in host re-
sponse to bacterial and viral pathogens and (iii) iden-
tifying driver genes and processes that contribute to
wound healing and response to anti-TNF therapy.
We provide relevant experimental validation that cor-
roborates the accuracy and advantage of our method.
INTRODUCTION
Genome-wide association studies (GWAS) and next-
generation sequencing technologies are rapidly providing
insights into genetic definitions of host susceptibility to
complex diseases (1–3). However, these approaches bring
with them the formidable task of deriving a functional un-
derstanding of how genetic variants lead to the dysregula-
tion of molecular pathways that underlies disease. The bot-
tleneck here is technologies that can directly report on the
functional state of a multitude of pathways that are simul-
taneously active or dysregulated in disease. Expression mi-
croarray or RNA-seq technologies enable comprehensive
monitoring of expression levels of genes but pose the ad-
ditional challenge of convolving such data into quantitative
pathway-centric measures. Conceptually, such a computa-
tionally inferred metric would be reflective of the functional
‘activity’ induced in a pathway and correlated to a macro-
scopic property such asmetabolic flux or signal flow. Identi-
fication of robust pathway activity measures continues to be
an active area of research for functional class scoring (FCS)
methods and recent studies have demonstrated their utility
in analysis of expression data from single perturbation stud-
ies or case-control studies (4–13).
FCS methods typically aggregate a gene-level statistic
into a single pathway-level metric, which could be either
univariate, such as mean or median of expression levels
(5), or multivariate, such as the Hotelling’s T2 statistic (14).
Comparative analyses have demonstrated considerable dif-
ferences in performance between such measures. Hwang
et al. (15) showed that these methods tend to produce dis-
cordant pathway activity signatures between related but in-
dependent datasets. Glazko et al. (16) showed that irrespec-
tive of the size and proportion of differentially expressed
genes, the power of any aggregate statistic is inversely pro-
portional to the amount of correlation present between
genes. It was hoped that pathway-based methods would be
an effective means of marker identification and disease clas-
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sification, but typically they have not been able to outper-
form gene-based methods.
Here, we present a computational method, named Mul-
tivariate Inference of Pathway Activity (MIPA), which em-
ploys a principal component analysis (PCA)-based cluster-
ing framework and uses five distinct clustering-based sum-
mary statistics to assess the magnitude and significance of
induced activity. A competitive analysis ensures that the ob-
served activity level is more significant than that estimated
for a random gene set with a comparable number of genes.
Themethod incorporates a new algorithm to identify a sub-
set of genes that may regulate the extent of activity induced
in a pathway. We demonstrate that our metric is linearly
sensitive to changes in both magnitude and proportion of
differentially expressed genes. MIPA’s sensitivity to changes
in correlation structure enables us to discriminate between
instances when the flux through a pathway is conserved ver-
sus when the flux is re-routed. We present an in-depth eval-
uation of specificity, robustness and reproducibility of our
method. We benchmarked MIPA’s false positive rate at less
than 1%.Using transcriptomic profiles representing distinct
physiological and disease states, we illustrate applicability
of our method in (i) identifying gene–gene interactions in
autophagy-dependent response to Salmonella infection, (ii)
uncovering gene-environment interactions in host response
to bacterial and viral pathogens and (iii) identifying driver
genes and processes that contribute to wound healing and
response to anti-TNF therapy. We provide relevant exper-
imental validation that corroborates the accuracy and ad-
vantage of our method.
Approach
Our pathway activity inference method is based on the fol-
lowing two premises: first, it is assumed that if a pathway
were transcriptionally regulated in a perturbed state, then
that set of samples would cluster together and be distin-
guishable from the set of control samples. This phenotypic
separation would exist in some feature dimension space de-
termined by gene expression data. Second, the magnitude
of separation between these clusters would be indicative of
the degree of activity induced in that pathway (Figure 1A).
In the present iteration, a PCA-based clustering frame-
work is used to assess the phenotypic separation between
the basal and perturbed states. The degree of activity in-
duced is quantified by computing the Euclidean distance
between paired samples in the n-dimensional principal com-
ponents space, where n is determined by the number of prin-
cipal components required to explain at least 90% of the
variance in the data. In the case of non-paired samples,
Mahalanobis distance is computed between each perturbed
sample and cluster of control samples. Based on the distri-
bution of activity induced in samples from the perturbed
group, the pathways are ranked as hyper-responsive, mildly
responsive or unresponsive (Figure 1B).
Besides the primary pathway activity measure, four ad-
ditional parameters are computed to evaluate the cluster-
ing tendency of two phenotypically distinct groups. Any
given pathway, if truly activated, would maximize these pa-
rameters (Figure 1C): (1) compactness, which ensures that
intra-cluster variability is small relative to the average inter-
cluster variability, (2) separation, which ensures maximum
separation between centroids of two clusters, (3) stabil-
ity, which checks whether the clusters are overly sensitive
to each sample within a group, and (4) representativeness,
which ensures that a pathway consists of genes that are rep-
resentative of a particular phenotype. The exact computa-
tions are outlined in the ‘Materials and Methods’ section.
We implemented a three-stage analytical pipeline to per-
form the following computations: beginning with an ex-
pression matrix of genes annotated in a pathway, Stage 1
(Figure 1C) computes five clustering-based measures and
assesses their significance using independent self-contained
tests; Stage 2 (Figure 1D) estimates the competitive signif-
icance of each pathway; and Stage 3 (Figure 1E) identifies
a subset of driver genes that govern the degree of activity
induced in each significant pathway. In Stage 1, sample la-
bels are randomly permuted to generate null distributions
for each parameter and significance of the estimated pa-
rameter is evaluated against these distributions. This is fol-
lowed by a competitive analysis in Stage 2 to ensure that the
observed activity level assessed with the given set of gene
annotations is more significant than the activity level esti-
mated for a random gene set with a comparable number of
genes. P-values for the competitive test are estimated using
a Student’s t-test on distribution of pathway activity mea-
sure alone (distribution being derived from activity estimate
per sample) between the observed groups in a given path-
way and the random gene sets simulated to contain similar
number of genes (gene permutations). AllP-value estimates
are adjusted formultiple hypothesis testing correction using
false discovery rate (FDR) controlling procedures. P-values
from self-contained tests are first combined using Stouf-
fer’s Z-score method into an overall single P-value. Only
pathways that score significantly on both resulting P-values
(combined P-value of self-contained tests and P-value from
competitive test) are considered significant. In Stage 3, up
to 1000 in silico simulations are executed in which genes are
sequentially added or removed to identify the minimum set
of genes that would recover 90% or more of the pathway
activity level observed with the full set. This subset is called
the driver gene set for a pathway. The complete algorithm is
outlined in the ‘Materials and Methods’ section.
MATERIALS AND METHODS
Pathway activity measure
Degree of pathway activity induced per sample is measured
using either the Euclidean distance between paired samples
or theMahalanobis distancemetric for non-paired samples.
Unlike the Euclidean distance measure, Mahalanobis dis-
tance takes into account the covariance of the control sam-
ples and is computed as
d(i ) =
√√√√
N∑
j=1
(
Y(i ) j − μ j x
)× S−1 × (Y(i ) j − μ j x
)
where μjx and S are the mean and covariance of the
principal-component scores for the control samples.
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Figure 1. A framework for pathway activity inference. (A) A PCA-based clustering framework is used to assess the phenotypic separation between the
basal and perturbed states. The degree of activity induced is quantified by computing the Euclidean distance between paired samples. (B) Based on the
distribution of activity induced in samples from the perturbed group, the pathways are ranked as hyper-responsive, mildly responsive and unresponsive. (C)
Four clustering-based summary statistics are computed to assess the magnitude and significance of induced activity. (D) Significance of observed activity
is compared with that estimated for a random gene set with comparable number of genes. (E) Up to 1000 in silico simulations are executed in which genes
are sequentially added or removed to identify the minimum set of genes that would recover 90% or more of the pathway activity level observed with the
full set.
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Compactness
Compactness of a cluster is estimated by computing the av-
erage Silhouette value over all data items. The Silhouette
value for an individual data item, which reflects the confi-
dence in a particular cluster assignment, is computed as
Si = bi − aimax(bi , ai )
where ai denotes the average distance between i and all data
items in the same cluster, and bi denotes the average dis-
tance between i and all data items in the closest other clus-
ter. The Silhouette width is limited to the interval [−1,1] and
should be maximized to ensure that intra-cluster variability
is smaller relative to the average inter-cluster variability.
Separation (Distance between the clusters)
Wards distance between clusters Ci and Cj is computed
as the difference between the total within-cluster sum of
squares for the two clusters separately, and the within-
cluster sum of squares resulting from merging the two clus-
ters in cluster Cij.
Dw(Ci ,Cj ) =
√√√√√
N∑
k=1
⎛
⎝∑
x∈Ci j
(x− ri j )2 −
⎡
⎣∑
x∈Ci
(x− ri )2 +
∑
x∈Cj
(x− r j )2
⎤
⎦
⎞
⎠
where ri is centroid of Ci, rj is centroid of Cj and rij is cen-
troid of Cij. This metric is similar to group average and cen-
troid distance but less susceptible to noise and outliers. The
distance between two clusters should be maximized.
Stability/Robustness
A stable cluster is one that is robust to the removal of a small
number of samples from the dataset. Using a jackknife ap-
proach, each sample is removed one at a time, following by
re-computation of the difference between the centroids of
the new clusters (in PCA space) from the original cluster.
This average distance between means is computed as
Dm(Cj ) = 1N
N∑
s=1
d
(
XS,iC , X
S,0
C
)
where XS,0C denotes the average principal-components score
profile for samples across cluster Cs,0 with full data of all
samples andXS,iC denotes the average principal-components
score profile for samples across cluster Cs,i obtained by re-
moving one sample at a time. N is the number of samples.
The average distance between means should be minimized.
Representativeness/Informativeness
This metric examines whether a pathway consists of genes
that are collectively representative of a particular pheno-
type. For a pathway i and its corresponding principal-
component scores in each PC-dimension j = 1, 2, . . . , N,
for the two phenotypic groups k= 1, 2 (for control and per-
turbed states), the following fixed effects model is fitted us-
ing one-way ANOVA:
P(i )jk = μ + μ jk + ε jk
where μ reflects the overall mean, μjk represents the effect
of phenotype group k on the samples’ principal-component
score and εjk is the random normal residual error term. Un-
der the null hypothesisH0: μ1 = μ2, the assumption is that
the two phenotypic group means are equivalent, or in other
words, that there are no changes associated between per-
turbed and control states. From this ANOVAmodel, the F-
statistic is computed as the ratio of the mean-squares from
the two groups. TheF-statistic captures the strength of asso-
ciation observed in a pathway’s principal-component score
profile over the different phenotype groups. Large values of
the F-statistic indicate a strong association whereas a small
F-statistic suggests that the samples demonstrate minimal
phenotype-specific score changes.
Driver gene identification
For each pathway, pairwise Euclidean distance between all
pairs of samples (control and treatment) is computed in the
PCA space. This set is designated as the null model PD0.
The following steps are executed for up to 1000 iterations,
dividing the samples at each iteration using a jackknife ap-
proach with 10% hold-out: (i) generate a randomly ordered
sequence of annotated genes; (ii) sequentially add (or re-
move) one gene at a time to the pathway annotation; (iii)
compute pair-wise Euclidean distance between all pairs of
samples in PCA space (PDG); (iv) estimate correlation be-
tween PD0 (with full annotation) and PDG; (v) compute dif-
ference in correlation yielded by having added the new gene;
(vi) for first 100 iterations, rank order genes by area un-
derROC curve (AUROC) andmax-pairwise-correlation be-
tween genes; (vii) for remainder iterations, rank order genes
by AUROC and history of difference in correlation yielded
by each gene. (viii) At the end of 1000 iterations, the follow-
ing steps are performed using the full dataset: (1) rank order
genes by AUROC and history of difference in correlation
yielded by each gene across 1000 iterations; (2) obtain cor-
relation gain profile by adding one gene at a time; (3) obtain
correlation loss profile by removing one gene at a time; and
(4) select set of ‘driver’ genes which when added sequentially
yield a correlation ≥0.9.
Performance benchmarking between MIPA variants
Six variants of MIPA were derived for benchmarking by
considering two distinct types of competitive tests and three
different ways of combining individual P-values (Figure 5).
In variants 1–3, null distributions of all 5 MIPA measures
were estimated by random permutation of gene labels and
P-value estimates were calculated for a gene set in each ob-
served dataset with respective nulls. In variants 4–6, null
distribution of pathway activity measure alone was gener-
ated by random permutation of gene labels and P-value es-
timates were calculated using Student’s t-test between the
distribution observed in the given dataset and that in ran-
domized gene sets. Furthermore, in variants 1 and 4, P-
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values from self-contained and competitive tests were inde-
pendently combined first using Stouffer’s Z-score method
and then using the larger value of the two as the final P-
value for a pathway (in this scenario, a pathway would score
only when P-values from both tests would be below the sig-
nificance threshold). In variants 2 and 5, P-values from all
tests were directly combined into a single overall value using
Stouffer’sZ-score method. In variants 3 and 6, independent
P-values were directly compared as is and the largest of the
values, across both self-contained and competitive tests, was
assigned as the final P-value for a pathway (in this scenario,
a pathway would score only when deemed significant by all
tests independently).
Datasets
Wound-associated epithelial transcriptional data analysis.
Whole genome transcription in normal epithelium and
wound-associated epithelium were profiled at days 2, 4
and 6 after colonic mucosal injury. The data was gener-
ated using Agilent’s whole mouse genome microarray 4 ×
44K platform. Raw data was log2 transformed, subject to
LOESS smoothing and quantile normalized. Gene expres-
sion data was aggregated from multiple probes per gene
using a maxMean function. Differentially expressed genes
were identified using three methods: (i) t-test and fold-
change at each time-point. Nominal P-values were esti-
mated by a t-test assuming unequal variance. Significant P-
values were selected for controlling FDR at 0.05 using a 2-
stage Benjamini, Krieger and Yekutieli multiple hypothesis
test correction method (17). 96 significant genes were iden-
tified on day 2, 589 significant genes on day 4 and 596 sig-
nificant genes on day 6. Genes that scored as significant in
at least two time points with absolute fold-change >2 were
selected. (ii) ANOVA on fold-change across time. Nomi-
nal P-values were estimated by a one-way ANOVA on fold-
change values across three days. Significant P-values were
selected for controlling FDR at 0.05 using the same meth-
ods as above.Geneswith absolute differences in fold-change
> 2 in at least two time points were selected. (iii) Marker se-
lection. Top 100 features were identified based on signal-to-
noise ratio using GSEA software. In total, 914 significant
genes were identified (Supplementary Table S6).
Salmonella infection in mice deficient in autophagy. Pro-
tocols for bacterial growth and infection were performed
as previously described, with slight modification (18). The
naturally streptomycin resistant Salmonella enterica serovar
Typhimurium SL1344 were grown for 8 h at 37◦C in LB
broth supplemented with ampicillin (50 g/ml) and subse-
quently diluted 1:1000 and cultured overnight under mild
aeration. Bacteria were washed twice in cold phosphate
buffered saline and resuspended at 108 CFU/50 l. The
S. TYPHIMURIUM strain used in this study has been en-
gineered to express a dsRed fluorescent protein and is ampi-
cillin resistant (19). Water and food were withdrawn 4 h
prior to treatment with 20 mg streptomycin in 75 l; im-
mediately following streptomycin treatment, water and food
were again provided. Twenty hours later, water and food
were again removed for 4 h, after which mice were infected
with 108 CFU S. Typhimurium. Water was resumed imme-
diately and food was provided 2 h post-infection.Mice were
sacrificed via CO2 asphyxiation at indicated time points and
tissues were harvested for RNA extraction.
Gene silencing and PBMC stimulation for Candida infection
study. Peripheral blood mononuclear cells (PBMC) were
isolated from healthy volunteers by Ficoll-Paque gradient.
After isolation 0.5 × 106 cells were plated into 96 round
bottom well-plates and left for 2 h at 37◦C to subsequently
transfect them with 25 nM NT5C3, CD38 siRNA (on tar-
get) or scrambled (non target) control siRNA (smartpool,
Thermo Scientific) for 48 h at 37◦C (Dharmafect, Thermo
Scientific). After a centrifugation step (8 min 1800 rpm),
supernatant was discarded and cell pellet was resuspended
in 200 l of RPMI (Dutch modified) containing Candida
albicans blastoconidia or Candida hyphae (both UC820, 1
× 106/ml, heat-killed at 100◦C for 1 h) for 24 h. Super-
natants were collected and IL-6 was subsequently measured
by enzyme-linked immunosorbent assay (ELISA) (Sanquin
Research, Amsterdam).
RESULTS
Multivariate pathway activity measures demonstrate linear
sensitivity to transcriptional regulation of annotated genes
We examined the sensitivity of our metrics with respect to
changes in degree and extent of significantly expressed genes
within a pathway using simulated datasets. To compare our
method with other activity inference schemes, five other ex-
pression summarizationmethods were implemented includ-
ing mean and median approaches (used in Guo et al. (5)),
multivariate Hotelling’s T2 statistic (developed by Lu et al.
(14)), PCA (similar to that used in Bild et al. (20)) and par-
tial least squares (PLS) regression (adapted from Liu et al.
(21)).
Two sample groups of equal size were simulated from p-
dimensional normal distributions N(μ1,Σ1) and N(μ2,Σ2)
representing two biological conditions with different out-
comes (such as control versus treatment), for a pathway
with p number of genes. To test the effect of decreasingmag-
nitude of transcriptional regulation, 20 distinct instances of
the simulated dataset were created by varying parameter ,
which controlled the average fold-change in expression of
all member genes. Parameter  was varied from ∼7-fold to
∼1.15-fold. To test the effect of decreasing extent of tran-
scriptional regulation, 20 distinct instances of the simulated
dataset were created by varying parameter ϒ , which deter-
mined the number of significantly upregulated genes. Pa-
rameter ϒ was varied from 19 to 0. Sensitivity was defined
as the degree of change induced in the activity measure for a
unit change in the independent parameter ( or ϒ). Graph-
ically, sensitivity represents the slope of a graph plotting the
change induced in activity measure versus the change in the
independent parameter.
We found our pathway activity measure to be sensitive
to changes in both parameters  and ϒ (Figure 2A and B),
and it demonstrated a linear relationship with the changes
in both parameters (Supplementary Figures S1 and S2). Be-
tween the two parameters, our primary metric was more
sensitive to the change in degree of transcriptional regula-
tion (parameter ). Among other measures, representative-
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Figure 2. Sensitivity analysis using simulated datasets and models. (A) Pathway activity measure changes linearly with uniform change in expression of
all annotated genes. (B) Pathway activity measure is linearly sensitive to change in number of significantly differentially expressed genes in a pathway. (C)
Median value of false positive rates for all MIPA measures matches the expected rate of 1% (dotted line). Performance of MIPA measures is comparable
with that of Mean and PCA methods. P-values from all 5 MIPA measures were combined using Stouffer’s Z-score method.
nesswas most sensitive to changes in both parameters while
compactness and robustness (stability) were the least re-
sponsive to parametric changes. In comparison, other FCS
methods also exhibited a fairly linear relationship but were
either extremely sensitive, such as Hotelling’s T2 statistic
(Supplementary Figures S3 and S4), or not sensitive at all,
such as the PLS method. Both mean and median were re-
sponsive to changes in parameters  and ϒ , but the degree
of change induced was less than moderate.
False positive rates ofMIPAmetrics are within an acceptable
range and comparable to that of PCA and mean methods
We analyzed the false positive rates of our metrics, as well
as other methods, using another set of simulations in Mat-
lab. The simulated datasets contained four gene sets with
5, 10, 20 and 50 genes respectively. Expression of 85 genes
for two groups was generated from a multivariate normal
distribution with mean vector μ and a diagonal variance-
covariance matrix . In this process, 85 elements of μ were
generated as uniform and random variables in interval (0,
10) and the 85 diagonal elements of  were generated as
uniform and random variables in interval (0.1, 10). The off-
diagonal elements of the variance-covariancematrix were
varied with a correlation (r) of 0.1, 0.3, 0.5, 0.7 and 0.9. The
simulation datasets were replicated 100× in each condition.
All simulation analyses compared the expression of a gene
set between two groups with the same mean expression lev-
els, each with a sample (N) of 10, 25 and 50 observations.
We estimated permutation P-values based on 500 permuta-
tions of samples in each condition. For our multivariate ac-
tivity metrics, we also estimated an overall P-value by com-
bining the P-values using Stouffer’s Z-score method. False
positive rates were estimated by the observed proportion of
replicates with a P-value <0.01 and 0.05.
Supplementary Table S1 shows the false positive esti-
mates, at an expected rate of 1%, for all tests for correla-
tions 0.1, 0.3, 0.5, 0.7 and 0.9; gene set sizes of 5, 10, 20
and 50, and sample sizes of 10, 25 and 50 in each group.
Overall, the median false positive rates for our metrics in
these simulated datasets are at the expected values of 1 and
5% (Figure 2C and Supplementary Figure S5). In compari-
son to other FCS methods, the performance of our method
is comparable to that of PCA and Mean algorithms, and
three of the other metrics, namely Hotelling’s T2 statistic,
Median and PLS had significantly larger false positive rates
than expected.
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Pathway activity measure is uniquely sensitive to changes in
correlation structure between member genes
We next hypothesized that significant changes in gene–
gene correlation structure can be informative of topologi-
cal changes in the regulation of a pathway. This could be
especially relevant when flux through a metabolic pathway
may be re-routed between two alternate terminal end points.
A pathway comprised of two influx arms (I1, I2) and three
efflux arms (E1, E2 and E3) (Figure 3A), was modeled to
test whether our method was sensitive to such changes. Us-
ing this specific topology, 22 distinct datasets were created
to simulate different scenarios of flux re-routing. These rep-
resented models varying from no regulation (Model 0) to
a fully upregulated pathway scenario (Model 21) (Supple-
mentary Figure S6). Model 5 (Figure 3A), representing the
state in which influx arm I2 and efflux arm E2 are upreg-
ulated, was selected as the reference model for basal state.
Ourmethodwas tested to examinewhether it could discrim-
inate between instances when this reference flux pattern was
conserved versus when it was not. Pathway activity levels
were first computed for the reference state and using this
‘learned’ response model, activity levels were estimated for
the other 21 states. A pairwise similarity matrix was com-
puted using the quantitative measures of all models, and
hierarchical clustering identified six distinct groups (Fig-
ure 3B; spearman rank correlation with complete linkage).
Using PCA-based clustering on pathway activity measures,
groups 5 and 6 clustered together and were distinct from the
remainder of the models (Figure 3C). A closer evaluation of
all the models from clusters 5 and 6 revealed that these clus-
ters indeed represented scenarios in which arms I1 and E2
were upregulated along with one or more other sub-arms
(Figure 3D). In comparison, none of the other FCS meth-
ods could discriminate between distinct modes of pathway
regulation (Supplementary Figure S7). We could not test
Hotelling’s T2 statistic in this analysis because that statis-
tic yields a single value for multiple samples within a group,
whereas our method estimates activity induced per stimu-
lated sample. This theoretical analysis confirmed that our
method can uniquely discriminate between instances when
a flux/signal is conserved versus when it is significantly re-
routed within the same pathway.
MIPA measures are independent and each contributes signif-
icantly to overall assessment of pathway analysis
To assess whether our multivariate pathway measures are
correlated and whether all parameters contribute equally to
discriminate between pathways, we examined a transcrip-
tional dataset profiling the response of human dendritic
cells to Mycobacterium tuberculosis (MTB) (22). Barreiro
et al. characterized the transcript expression levels in pri-
mary dendritic cells from 65 individuals, before and after
infection with MTB, generating more than 250 microarray
samples. We selected this study because it provides a large
sample size for a pathogen-specific transcriptional response
in a single primary cell type, making it ideal for correlation
and robustness analysis.
We obtained the log2 normalized expression matrix
directly from the Gene Expression Omnibus (GEO)
(GSE34151) and processed it with our pathway activity
computation pipeline. We computed a matrix of MIPA
measures for 156 KEGG pathways and subjected it to a
principal components analysis. As shown in Figure 4, a bi-
plot of the loading coefficients for all measures and princi-
pal components scores for each pathway, the first two com-
ponents account for considerable fractions of variance in-
dependently (∼60% in first component, ∼29% in second
component). Additionally, the loading coefficients are con-
siderably different for each measure between the first two
components, and each measure dominates uniquely in one
of the five principal components (Supplementary Table S2).
We also computed pairwise linear correlation coefficients
between these measures and found all to be less than 0.6
(Supplementary Table S3) with the exception of Activity
and Separation which was 0.82.
To further assess the contribution of each of the five pa-
rameters to the overall/final assessment of pathway signif-
icance, we computed the number of pathways that scored
significantly by MIPA, first by using all five features, and
then by removing one feature at a time (Table 1). We also
evaluated whether the quality of the P-values estimated
was significantly affected. We compared the P-values of the
pathways between those estimated with all five measures
versus ones obtained by removing just one feature using a
single sample t-test with the null hypothesis that the differ-
ences would be centered on zero with unknown variance. As
shown in Table 1, we found 57 pathways that scored signifi-
cantly when using all five features. Exclusion ofActivity and
Separationmeasures had the most significant impact on the
number of pathways that scored, and the results clearly in-
dicate that loss of either of these onemeasures was not com-
pensated by the other. Likewise, exclusion of all three other
measures also resulted in either a loss or gain of number of
significant pathways. Notably, exclusion of the Robustness
parameter yielded almost twice as many significant path-
ways. To further assess the underlying cause for this result,
we evaluated the PCA clusters for each additional pathway
that scored. We found that each of these pathways exhib-
ited large intra-group variance coupled with distinct sub-
clusters within the phenotypically similar groups of con-
trol and stimulated samples (data not shown). Such a clus-
tering phenomenon is deemed unstable by the Robustness
measure and hence these pathways did not score with the
original MIPA analysis of this dataset. We did not find any
basis for technical noise or batch-specific differences in nor-
malized gene expression data, which can typically manifest
in large cohort studies, and which could explain this sub-
clustering phenotype.We hypothesize that the true source of
this phenomenon might be traceable to either demographic
differences (e.g. age, gender, ethnicity) or genotypic differ-
ences within this cohort (e.g. genotypic differences resulting
in eQTLs that lead to differential activity patterns within a
pathway). If the latter were true, this finding would suggest
that our pathway activity measure might have utility in de-
tecting pathway-response-QTLs. These results collectively
suggest that all MIPA measures are independent and each
contributes significantly to overall assessment of pathway
analysis.
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Figure 3. (A) A model pathway comprising of two influx arms (I1, I2) and three efflux arms (E1, E2, E3). (B) Pairwise similarity matrix, subject to
hierarchical clustering, identifies six distinct clusters. (C) PCA-based clustering of pathway activity measures segregates models into two distinct groups,
one that contains models from clusters 5 and 6 and another that contains the remainder of the models. (D) Models in clusters 5 and 6 include the reference
model 5 and all other instances when the flux through influx arm I1 and efflux arm E2 is preserved.
Table 1. Relative impact of each MIPA measure on overall assessment of significant pathways
Feature removed # Significant pathways
t-test to assess significant differences in estimated
P-values of pathways
None 57 N/A
Avg. activity per sample 11 4.48E-42
Compactness 48 1.18E-13
Separation 11 1.15E-37
Robustness 92 1.81E-45
Informativeness 65 8.51E-07
Each of the MIPA measures were removed independently, one feature at a time, to assess the impact on the number of pathways being scored significantly
relative to the original assessment when none of the features were removed. Quality of the significance profile was also assessed by single sample t-test of
differences in log-transformed P-values.
Comparative analysis of MIPA with other FCS methods
benchmarks its performance and false positive rate at less
than 1%
Formal error rate estimation for pathway analysis methods
has been usually stymied by lack of gold standards. Typical
validation approaches include citations to supporting evi-
dence either from existing literature or from results of gene
set enrichment analysis (GSEA) (23). However, a recently
published study presented a systematic approach for assess-
ment of gene set analysis methods in terms of Sensitivity,
Prioritization and Specificity (24). Briefly, the framework
proposes that any gene set analysis method, when applied
to a disease-specific microarray of control and disease sam-
ples, should score the corresponding disease-relevant path-
way among the top pathways. Subsequently, each method
is evaluated in its ability to (i) produce small P-values for
the relevant gene sets (Sensitivity), (ii) rank close to the
top these context-relevant gene sets (Prioritization) and (iii)
not generate more false positive rates than expected (Speci-
ficity). Their analysis identified Pathway Level Analysis
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Figure 4. PCA analysis of matrix of MIPAmeasures for 156 KEGG path-
ways. Relative impact of each MIPAmeasure on overall assessment of sig-
nificant pathways is presented in Table 1.
of Gene Expression (PLAGE), GLOBALTEST and Path-
way Analysis with Down-weighting of Overlapping Genes
(PADOG) as the best overall gene-set analysis methods.
PLAGE (12) decomposes gene expression variance in
each gene set using singular value decomposition. GLOB-
ALTEST (25) uses a logistic regression model to determine
if samples with similar profiles have a similar phenotype.
PADOG (26) computes a gene set score as the mean of ab-
solute moderated t-scores weighed inversely with the gene
frequency across all gene sets analyzed. We benchmarked
MIPA against these previously published performance re-
sults of other gene set analysis methods.
We obtained the normalized microarray datasets for 42
studies, totaling to >1400 samples, from Tarca et al. We
also received gene set annotations for 259 KEGG path-
ways and 88 Metacore Disease Biomarker Networks. Each
dataset studied one of 19 unique conditions/diseases for
which KEGG orMetacore had designed a specific gene set.
For each dataset independently, we first applied MIPA to
estimate the P-value for all gene sets and sorted them from
lowest to highest P-value. We then computed the rank of
the target gene set (specific to that disease dataset) as a per-
centage ranging from ∼0 to 100% (small rank values would
indicate that the target gene set was prioritized as relevant).
Next, we ran our method on 50 phenotype permuted ver-
sions of each of the 42 datasets as outlined earlier (24). We
counted the number of gene sets with a P-value <0.01 and
0.05 under this null hypothesis and expressed this number
as a percentage of the total number of tests.
In this comparative analysis, we analyzed the perfor-
mance of six different variants of MIPA (outlined in ‘Mate-
rials and Methods’ section; Figure 5). Table 2 summarizes
the performance parameters for each of these six variants.
For a given competitive test of choice, we found that the
approach of combining P-values using Stouffer’s Z-score
method resulted in higher sensitivity than simply taking the
largest of the P-values across all tests. However, combining
P-values directly (variants 2 and 5) resulted in very large
false positive rates. Variants 1 and 4, both of which use the
approach of combiningP-values separately first, performed
extremely well on all parameters, with variant 4 achieving
false positive rates of less than that expected at random
(1%).
We compared the performance scores of our method
(variants 1 and 4) with those already reported for 16 other
FCS methods (Table 1 in (24)). We re-normalized the prior-
itization score and sensitivity surrogate into Z-scores after
adding data for our method. Previous analysis segregated
the methods into two categories, based on the false posi-
tive rates observed with each method, and generated sep-
arate rankings for the two. Category 1 methods generated
the expected (or close to expected) number of false posi-
tives whereas Category 2 methods had much larger false
positive rates under the null hypothesis. Our method,MIPA
(variants 1 and 4), clearly would be classified as Category 1
based on their Specificity profiles. The previous study did
not use Sensitivity data when ranking the methods in Cate-
gory 1. We produced two overall rankings, one with Speci-
ficity incorporated abnd the other without. Supplementary
Table S4 summarizes these overall rankings. Variant 1 of
MIPA was the top-scoring method and outperformed all
other methods in the comparison. Variant 4 of our method,
which has a better Specificity profile than variant 1, ranked
second after PLAGE but has a superior false positive rate.
Finally, we examined theRobustness (or Reproducibility)
of ourmethod as considered by Li et al. (27).We utilized the
transcriptional dataset from Barreiro et al. (22) and derived
50 resampled subsets by randomly selecting 78 paired sam-
ples, with <50% sample overlap between the subsets. We
counted the number of gene sets that scored withMIPA (P-
value < 0.01). We found that in spite of random resampling
from the same large set, the number of gene sets called sig-
nificant by MIPA did not vary greatly from one set to the
other (Supplementary Figure S8). On average,∼60 gene sets
scored across this resampling analysis (standard deviation
= 6 pathways).When compared to the results from applying
MIPA to the full dataset, we found 57 significant pathways,
of which 40 scored in at least 80% of the resampled datasets.
From this resampling analysis, we conclude that MIPA is
fairly robust and that we can expect the end results to be
fairly reproducible and transferable across similar datasets.
Up to 1000 iterations are sufficient for identification of driver
genes
We analyzed whether 1000 permutations were enough for
the identification of driver genes in pathways annotated
with varying number of genes. We generated simulated
datasets that contained four gene sets with 5, 10, 25 and
50 genes. Expression of genes for two groups was generated
from a multivariate normal distribution with mean vector
μ and a diagonal variance-covariance matrix . The off-
diagonal elements of the variance-covariancematrix were
varied with a correlation of 0 to 0.5 and the difference be-
tween the means of two groups was set to 5. We applied our
driver gene identification algorithm to each of these gene
sets and varied the number of allowed iterations from 100
to 4000 in steps of 100. Each iteration produced a rank-
ordered list of genes per pathway, which was saved to build
a single matrix of rankings assigned to each gene across all
runs.Next, we computed the Spearman rank correlation co-
efficient between each ranking from a run and the ranks ob-
tained at the final runwith 4000 iterations. As shown in Sup-
plementary Figure S9, the correlation coefficient increases
Nucleic Acids Research, 2014, Vol. 42, No. 16 10297
5 self-contained
tests
Combine with
Stouffer’s Z
MAX
5 competitive
tests
Combine with
Stouffer’s Z
5 self-contained
tests
5 competitive
tests
5 self-contained
tests
5 competitive
tests
Combine with
Stouffer’s Z
5 self-contained
tests
1 competitive
test
Combine with
Stouffer’s Z
MAX
5 self-contained
tests
1 competitive
test
MAX
A B C
D E F
(Variant 1)
5 self-contained
tests
Combine with
Stouffer’s Z
MAX
1 competitive
test
(Variant 4)
(Variant 2) (Variant 3)
(Variant 5) (Variant 6)
Figure 5. Six variants of MIPA approach. In Variants 1–3 (panels A, B, C), competitive tests evaluate all five measures, just like self-contained tests.
Variants 4–6 (panels D, E, F) use a single t-test between the distribution of pathway activity measures observed per sample in the given dataset and that
in randomized gene sets. Variants 1 and 4 (panels A, D) combine P-values using Stouffer’s Z-score method and then use the larger value of the two as the
final P-value for a pathway. Variants 2 and 5 (panels B, E) directly combine the P-values from all tests into a single overall value using Stouffer’s Z-score
method. Variants 3 and 6 (panels C, F) assign the largest P-value as the final value for a pathway.
Table 2. Comparative performance of six variants for MIPA in their ability to (i) produce small P-values for the relevant gene sets (Sensitivity), (ii) rank
close to the top these context-relevant gene sets (Prioritization) and (iii) not generate more false positive rates than expected (Specificity)
Method P-value (sensitivity) % Rank (prioritization) False positive rate (specificity)
Median Mean Median Mean 1% 5%
MIPA var 1 0.0025 0.2682 23.5812 30.9202 2.5427 5.0149
MIPA var 2 0.0000 0.1132 3.3994 22.2025 14.2291 19.2215
MIPA var 3 0.9200 0.8329 79.4737 73.3134 0.0000 0.0000
MIPA var 4 0.0299 0.3079 44.2210 47.2948 0.7354 1.1496
MIPA var 5 0.0000 0.0777 6.2500 25.1189 27.9256 36.4886
MIPA var 6 0.7900 0.7152 64.1938 61.3367 0.0000 0.0001
asymptotically and typically exceeds 0.8 in runs with as few
as 500 iterations. This result illustrated that up to 1000 it-
erations were sufficient to use in the identification of driver
genes per pathway.
Higher sensitivity of MIPA identifies pathways not enriched
in GSOA and GSEA
Based on the outcome of our sensitivity analysis on sim-
ulated data and comparative performance analysis, we hy-
pothesized that our method would be able to detect regu-
lation even in the presence of small coordinated transcrip-
tional change across several genes in a pathway. This would
be particularly advantageous in detecting instances when
small regulation of a critical gene, such as a bottleneck en-
zyme in a metabolic pathway or an adaptor molecule for a
signaling complex, would have significant impact in the out-
put of the pathway. The efficacy of our method was tested
using transcriptional profiles of intestinal injury and wound
healing (28). Seno et al. developed an in vivo acute injury
system, analogous to punch biopsy of the skin, which al-
lowed them to generate temporal profiles of intestinal ep-
ithelial injury as it progressed through the various phases of
healing. They showed that Trem2 was essential to promote
healing of wounds in the colon. We applied our method
to identify pathways that are differentially regulated during
this wound healing process.
After initial normalization and pre-processing (described
in ‘Materials and Methods’ section), the transcriptomics
dataset was subject to our pathway activity analysis
pipeline. Our method identified 49 pathways as significant
at FDR < 0.25 (Supplementary Table S5). These included
several of the well-known pathways and processes that are
regulated in wound-healing response such as the cytokine–
cytokine receptor interactions and growth-factor driven sig-
naling (ErbB signaling) (29). Also, the activation of pattern
recognition receptors, such as NOD-like and RIG-I-like re-
ceptors that are instrumental in detecting various pathogens
and generating innate immune responses, are suggested to
play an essential role in maintenance of gut homeostasis
(30). Other specific signaling pathways that also scored in
our analysis and have been identified for their role in wound
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healing include MAPK, JAK-STAT and NFB signaling
(31,32).
We next identified 643 driver genes for the set of 49
pathways (Supplementary Table S5), 79 (12.3%) of which
showed locally significant differences between the two tis-
sue groups (ANOVA, FDR < 0.05; Figure 6A). A hyper-
geometric test was used to rank-order pathways based on
the enrichment of driver genes that scored as significantly
differentially expressed at the whole-genome level. Four
pathways scored with significant P-value < 0.05, which in-
cluded signaling pathways of cytokine receptors and growth
factors, and metabolic pathways of glutathione and his-
tidine metabolism (Table 3). Collectively, these pathways
and their select driver genes represent suitable targets for
functional validation. Histidine metabolism, in particu-
lar, has been shown to accelerate the wound-healing pro-
cess (33) and ameliorate murine colitis (34). Our analy-
sis identified HDC1, ABP1 and MAOA as the significant
driver genes in this pathway (Figure 6B). Using network-
building algorithms in MetaCore (Thomson Reuters; Ref:
http://thomsonreuters.com/metacore/), we identified regu-
latory paths from these driver genes to Trem2 (Supplemen-
tary Figure S10). Our model suggests that collective up-
regulation of HDC1 and down-regulation of ABP1 and
MAOA, lead to increased accumulation of histamine, which
activates Trem2 and accelerates the wound healing process.
We compared the performance of our method with two
other popular methods for identifying significant pathways,
namely, gene set overlap analysis (GSOA)(35) and GSEA
(23). The two methods identified very distinct signatures
of pathways with overlap as little as 20%. GSEA identified
40 gene sets as significantly enriched (Q-value ≤ 0.25, Sup-
plementary Tables S7 and S8), while GSOA identified 49
enriched gene sets (Q-value < 0.05, Supplementary Tables
S9 and S10) on the basis of 914 significantly differentially
expressed genes (Supplementary Table S6). Comparatively,
our method identified 25 pathways that were not reported
by either GSEA or GSOA. These included several well-
known processes in wound-healing response such as NFB
signaling and RLR/NLR signaling. Histidine metabolism,
identified as one of the key pathways for the wound healing
process by our method, did not score as significant with ei-
ther GSEA or GSOA. As shown in Table 4, most of these
pathways had either none or just a few significantly differen-
tially expressed genes, which explains why these were not en-
riched. This observation clearly illustrated that our method
was indeed able to detect pathways already known to be as-
sociated with wound healing, even when there was low tran-
scriptional regulation of annotated member genes.
MIPA identifies novel targets of Atg16l1 during response to
Salmonella infection
Our group recently demonstrated that loss of expression
of the essential autophagy protein Atg16l1 in intestinal
epithelial cells decreased autophagic engulfment of S. Ty-
phimurium, resulting in hyper-inflammation and systemic
bacterial translocation in infected mice (36). To gain fur-
ther insight into other pathways and genes that are regu-
lated by Atg16l1, we generated transcriptional profiles of
ileal tissue from wild-type mice and mice deficient in au-
tophagy in epithelial cells (Atg16l1f/f xVillin-cre) or Cd11c+
cells (Atg16l1f/f x Cd11c-cre), after in vivo infection with
Salmonella.
After initial pre-processing and normalization of tran-
scriptional data (see ‘Materials and Methods’ section), our
method identified 13 pathways regulated in response to
Salmonella infection in wild-type intestinal epithelial cells.
These included regulation of autophagy, the TGF sig-
naling pathway, steroid biosynthesis and several metabolic
pathways (Supplementary Table S11). The induced activ-
ity levels for these select pathways were cross-compared
with those predicted for autophagy-deficient mice, and
were subjected to PCA-based clustering. These 13 pathways
formed a robust basis to discriminate betweenwild-type and
autophagy-deficient groups (Figure 7A). The response to
Salmonella infection from Atg16l1f/f x Cd11c-cre mice was
similar to that observed in wild-type mice, but the samples
from Atg16l1f/f x Villin-cre mice were clearly distinct from
both of the other groups. These results are consistent with
our in vivo analysis of these mice, in which we observed that
Atg16l1f/f x Villin-cre had increased systemic inflammation
following infection with S. Typhimurium, but that there
were few such differences between Atg16l1f/f x Cd11c-cre
and wild-type mice. Amongst these 13 pathways, we evalu-
ated the loading coefficients along the first principal com-
ponent, which accounted for >50% variance in the data,
and could readily discriminate between the three groups.We
found that activity measures from pathways of tryptophan
metabolism, taste transduction and TGF-ß signaling con-
tributed most significantly to the observed separation be-
tween sample groups (Figure 7B). Two of these pathways
have recently been shown to be associated with autophagy.
Wauson et al. (37) have demonstrated that reduced expres-
sion of taste receptor complex T1R2/T1R3 accelerates au-
tophagy while Fougeray et al. have reported that depletion
of tryptophan mediates activation of IFN-ϒ-induced au-
tophagy (38).
Next, we identified the driver genes for this set of 13
significant pathways and compared the differences in their
expression fold-change between wild-type and autophagy-
deficient samples (ANOVA; P-value < 0.05) to identify 16
genes that were significantly dysregulated in Atg16l1f/f x
Villin-cre samples (Figure 7C). These included previously
reported regulators of autophagy, namely Ifna6,Pik3r4 and
Pik3c3. The other notable genes included members of the
bile secretion pathway (Slc4a4, Slc9a1), gene Gls from the
bicarbonate reclamation pathway and Tas2r121 from the
taste transduction pathway. Tas2r121 belongs to the fam-
ily of bitter taste receptors that are being increasingly rec-
ognized for their prominent role in ‘sensing’ the luminal
content of mucosal surfaces and affecting gastrointestinal
function and glucose metabolism (39). In a recent report
Lee et al. provide evidence that these receptors also function
as regulators of innate immunity and antimicrobial defense
in the human upper respiratory tract (40). Such cell type-
specific autophagy-dependent regulation of pathways may
have important implications for host response to infection.
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Table 3. Top-scoring wound healing response pathways and key driver genes identified by MIPA
Pathway
MIPA
(P-value) Driver genes GSEA GSOA
Glutathione metabolism 0.0182 Gstm1, Gstm2, Gstm3, Gsta1, Gsta3 Down Down
Cytokine-cytokine receptor interaction 0.0151 Tnfrsf11a, Inhba, Il1b, Cxcl10, Cxcl5, Egfr,
Cxcl16, Cxcr4, Osmr
Up Up
ErbB signaling pathway 0.0479 Erbb4, Hbegf, Cdkn1a, Egfr Up Up
Histidine metabolism 0.0455 Abp1, Maoa, Hdc N.D. N.D.
Table 4. Wound healing response pathways uniquely identified by MIPA
Path
#
Annotation
genes
# Driver
genes
#
Sig.diff.genes
Min rank
SNR
Mean rank
SNR
Median
rank of
genes
Max rank
SNR
Pentose and glucuronate
interconversions [Path:mmu00040]
27 17 1 2974 9833.75 11119 12969
Synthesis and degradation of
ketone bodies [Path:mmu00072]
9 6 0 164 9381 10206.5 13030
Ubiquinone and other
terpenoid-quinone biosynthesis
[Path:mmu00130]
10 7 1 2863 9709.2 11022.5 13104
Purine metabolism
[Path:mmu00230]
151 14 0 68 7549.297297 8185.5 13011
Histidine metabolism
[Path:mmu00340]
28 11 3 7 8406.884615 10023 13052
Phenylalanine, tyrosine and
tryptophan biosynthesis
[Path:mmu00400]
7 6 0 2863 7231.8 6535 12654
Cyanoamino acid metabolism
[Path:mmu00460]
4 2 0 920 9397.5 11898.5 12873
N-Glycan biosynthesis
[Path:mmu00510]
47 5 1 368 8320.069767 9924 12896
Glycosaminoglycan degradation
[Path:mmu00531]
18 9 1 1280 7398.176471 7623 13057
Sphingolipid metabolism
[Path:mmu00600]
38 14 0 116 6852.361111 7554 12667
Glycosphingolipid
biosynthesis––globo series
[Path:mmu00603]
14 9 1 640 7690.928571 8637 13057
Glyoxylate and dicarboxylate
metabolism [Path:mmu00630]
22 6 0 4254 10423.14286 11506 13065
Butanoate metabolism
[Path:mmu00650]
27 5 0 164 9840.72 11173 13095
One carbon pool by folate
[Path:mmu00670]
16 9 2 1344 7574.25 7336 13100
Riboflavin metabolism
[Path:mmu00740]
12 8 0 3563 8754.333333 8901.5 12512
Retinol metabolism
[Path:mmu00830]
63 38 4 38 7639.296296 7795 12975
NF-kappa B signaling pathway
[Path:mmu04064]
84 13 0 14 4212.3125 2738 12849
Phagosome [Path:mmu04145] 150 26 1 46 4590.588785 3630 13107
NOD-like receptor signaling
pathway [Path:mmu04621]
47 8 0 14 5028.02381 3771 13145
RIG-I-like receptor signaling
pathway [Path:mmu04622]
59 11 1 24 4681.5 3239 12736
T cell receptor signaling pathway
[Path:mmu04660]
106 27 1 97 4902.640777 3850 12928
Adipocytokine signaling pathway
[Path:mmu04920]
66 16 2 87 5438.153846 5423 12745
Salivary secretion
[Path:mmu04970]
70 28 1 589 5852.044776 5043 12497
Bile secretion [Path:mmu04976] 65 29 2 271 6512.473684 6275 13131
Vitamin digestion and absorption
[Path:mmu04977]
21 14 1 634 6075.142857 6180 12390
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Figure 6. Pathway activity analysis of wound-healing response. (A) Seventy-nine driver genes identified from 49 pathways that scored significantly with
MIPA analysis. (B) Differentially regulated driver genes of histidine metabolism.
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Comparative MIPA identifies nicotinamide metabolism
specifically required for anti-fungal response
In a recent report, type 1 interferon signaling was recently
identified as a critical pathway for host defense againstC. al-
bicans (41). Using a whole-genome transcriptional dataset
of human primary cells stimulated in vitro with bacterial
and fungal agents, the previous bioinformatics approach fo-
cused on analysis of signaling pathways (MetaCore) and
reported interferon signaling to have the strongest enrich-
ment within this set. We sought to use our newly developed
approach to identify metabolic pathways that may be addi-
tionally regulated.
Normalized transcriptional profiles of 300 peripheral
blood mononuclear cell (PBMC) samples were sourced
from healthy individuals, at 4 and 24 h following stimula-
tion with five different Toll-like receptor (TLR) ligands and
microbes (C. albicans, Escherichia coli-derived lipopolysac-
charide (LPS),Borrelia burgdorferi,MTB, or control RPMI
culture medium). Application of our method to each stim-
ulus and time point separately yielded distinct sets of path-
way signatures for LPS, MTB, Borrelia and Candida re-
sponse at 4 and 24 h (SupplementaryTables S12–S19). Path-
ways with significant P-values were corrected to control for
FDR < 0.1 using a 2-stage Benjamini, Krieger and Yeku-
tieli multiple hypothesis test correction method (17). Stimu-
lation by Candida resulted in activation of 60 pathways at 4
h post-stimulation, which was more than twice the number
of pathways, on average, that were active at the same time
point in response to LPS, MTB or Borrelia. A compara-
tive gene expression analysis yielded a similar trend for the
number of differentially expressed genes for each stimulus
(data not shown). To identify stimulus-specific pathways, a
matrix of activity measures from all sample groups was as-
similated and subjected to a one-way ANOVA. We selected
44 pathways with significant P-values corrected for FDR <
0.1 (Supplementary Figure S11A).
Using the driver gene identification algorithm coupled
with an ANOVA test, pathway- and stimulus- specific genes
were identified at FDR < 0.01 (Supplementary Figure
S11B). GSOA of this list of key driver genes, using canon-
ical pathway annotations from Reactome and Biocarta in
mSigDB, yielded a strong enrichment for interferon signal-
ing, as was previously reported (Supplementary Table S20).
Four of the top 10 genes in this list were validated in the
original study, namely IFNG, CCL8, CXCL10 and ISG15.
Another noteworthy driver gene in this list was IDO1
from the tryptophan metabolism pathway (Figure 8A). We
and others have previously reported data (42) validating
Candida-specific upregulation of IDO1 and the role of tryp-
tophan metabolism in host defense againstCandida. To pri-
oritize among the 44 selected pathways for functional vali-
dation, we evaluated which of these pathways were enriched
for the set of stimulus-specific driver genes identified in the
last step. We used a hypergeometric test to assess the signifi-
cance of each pathway and adjusted these P-values with the
Benjamini-Hochberg method to control for FDR < 0.25.
Ten pathways scored (Table 5), most of which were well-
studied signaling pathways in the context of stimulation
by TLR ligands. Nicotinamide metabolism pathway was a
novel metabolic pathway that scored in this list with signifi-
cant upregulation of two driver genes, CD38 and NT5C3,
specifically in context of stimulation by Candida (Figure
8B and C). Nicotinamide metabolism acts downstream of
the tryptophan metabolic pathway and leads to the gener-
ation of nicotinamide from NAD+ and NADP. Based on
these findings, and the results of our pathway activity analy-
sis, we tested the hypothesis that activation of nicotinamide
metabolism, via the upregulation of CD38 and NT5C3,
would be involved in the stimulation of immune cells specif-
ically by C. albicans.
We knocked down CD38 and NT5C3 ex vivo in PBMCs
isolated from healthy individuals and stimulated these cells
with two distinct forms of Candida, namely Candida coni-
dia and Candida hyphae. C. albicans is a dimorphic fun-
gus that can be present in both of these two morphotypes
when stimulated or activated. Twenty-four hours post-
stimulation, cell cultures were profiled for interleukin (IL)-6
production, a critical cytokine required for defense against
Candida (43). Of the eight donors used to study the ef-
fect of knocking down NT5C3 on the response to Can-
dida conidia, significant downregulation in IL-6 production
was observed in six cases (P-value = 0.0169; Figure 8D). In
the case of infection with Candida hyphae, a reduction in
IL-6 production was observed when NT5C3 was knocked
down; however, the results were not significant (P-value =
0.1858) (data not shown). Knockdown of CD38 had a sig-
nificant impact on IL-6 production in response to Candida
conidia (P-value = 0.0385; Figure 8E). These experimental
findings validated the hypothesis predicted by our method
that upregulation of nicotinamide metabolism is essential
for mounting a successful anti-fungal program in human
PBMCs.
MIPA identifies a microbiome-dependent pathway associated
with therapeutic response
To test whether our pathway activity measure could serve as
a basis for stratifying patients and understanding therapeu-
tic response, we analyzed publicly available mRNA expres-
sion in mucosal biopsies taken from inflammatory bowel
disease (IBD) responders and non-responders to infliximab
treatment (44). Infliximab is an effective treatment for ul-
cerative colitis (UC) with >60% of patients responding to
treatment and up to 30% reaching remission.However, anti-
TNF treatments such as infliximab involve high costs of
treatment and show wide variance in clinical efficacy and
outcomes. Certain patients may benefit more than others,
but we lack reliable predictors of treatment outcome that
could help stratify patients who would benefit most from
such treatment. Previous attempts to derive pathway signa-
tures using enrichment methods of differentially expressed
genes have failed to induce changes in clinical practice.
We applied our method to the transcriptional profiles of
biopsy samples collected from patients with clinically active
UC (Mayo score > 6). These patients were treated with in-
fliximab or placebo at weeks 0, 2, 6 and every 8 weeks there-
after until 30 weeks; biopsies were collected at baseline and
at the 8 and 30 week timepoints. The patients were stratified
into four groups: infliximab responders (n= 14), infliximab
non-responders (n = 15), placebo responders (n = 6) and
placebo non-responders (n = 8).
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Table 5. Top-scoring TLR stimulation-specific response pathways identified by MIPA
Pathway
Fraction of
stimulus-
specific driver
genes (per
pathway)
Fraction of
stimulus
specific driver
genes
(background) P-value Q-value
Toll-like receptor signaling pathway [Path:hsa04620] 0.1164 0.0138 0.0000 0.0000
Chemokine signaling pathway [Path:hsa04062] 0.0714 0.0138 0.0000 0.0000
Cytokine-cytokine receptor interaction [Path:hsa04060] 0.0529 0.0138 0.0000 0.0000
RIG-I-like receptor signaling pathway [Path:hsa04622] 0.0750 0.0138 0.0006 0.0044
NF-kappa B signaling pathway [Path:hsa04064] 0.0723 0.0138 0.0007 0.0044
Cytosolic DNA-sensing pathway [Path:hsa04623] 0.0694 0.0138 0.0024 0.0123
Osteoclast differentiation [Path:hsa04380] 0.0333 0.0138 0.0244 0.0988
PI3K-Akt signaling pathway [Path:hsa04151] 0.0027 0.0138 0.0255 0.0988
Nicotinate and nicotinamide metabolism [Path:hsa00760] 0.0909 0.0138 0.0329 0.1134
Jak-STAT signaling pathway [Path:hsa04630] 0.0259 0.0138 0.0770 0.2388
Our method identified 39 pathways that showed signifi-
cant regulation trends in infliximab responders at week 30
post-treatment. The loading coefficients, computed within
the PCA framework, formed the ‘pathway response model’
(39 models in total). Application of these models to
the transcriptomics data from infliximab non-responders
yielded the ‘predicted’ level of activity induced. Our hypoth-
esis was that the pathways essential for mounting a favor-
able response to infliximab treatment would be predicted to
have lower activity levels in the non-responder population.
Comparative analysis of ‘observed’ and ‘predicted’ activity
levels identified 11 pathways that were significantly upregu-
lated in infliximab responders. PCA-based clustering analy-
sis of the matrix of activity measures demonstrated the effi-
cacy of these pathways in discriminating between clusters of
responders and non-responders at week 30 (Figure 9A). A
similar trend was observed with the transcriptomics profile
at week 8 post-treatment (Figure 9B).
To identify which of the 39 pathways were specific to in-
fliximab response, the predicted activity levels of placebo
responders were analyzed in the same manner as that for
infliximab non-responders. Thirty pathways were found to
be shared between the two groups of responders. Combin-
ing the 9 pathways that were not regulated in placebo re-
sponders with 11 pathways not regulated in infliximab non-
responders, a total of 18 infliximab response-specific path-
ways were identified (Supplementary Figure S12A). To test
the discriminatory power of these 18 pathways, activity val-
ues from all patients, observed and predicted, were aggre-
gated into a single matrix and subjected to PCA-based clus-
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Figure 9. Pathway activity analysis of infliximab response in ulcerative colitis (UC). PCA-based clustering analysis of pathway activity measures for
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tering. We found that 80% of variance could be explained
with the first three principal components and that the four
patient groups clustered distinctly from each other (Fig-
ure 9C).
To establish a molecular basis for the differences between
infliximab responders and non-responders, we applied our
driver gene identification algorithm to the 11 pathways
that were predicted to be downregulated in non-responders
and identified 44 genes that were differentially expressed in
the non-responders. Our top-scoring gene was 3-hydroxy-
3-methylglutaryl-CoA synthase 2 (HMGCS2) (Supplemen-
tary Figure S12B) from the ketogenesis pathway, which ex-
hibited a >50-fold change at the end of 30 weeks of inflix-
imab treatment in the responder group but was largely not
expressed in the non-responder group (Figure 9D). Our sec-
ond best scoring genewas aquaporin 8 (AQP8) from the bile
secretion pathway, which was upregulated>50-fold in most
of the infliximab responders by week 30 (Figure 9E). In
comparison to the group of placebo responders, we found
that the activation of these genes is uniquely associated with
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infliximab treatment. A t-test-based evaluation of the dif-
ferences between expression levels before and 30 weeks af-
ter treatment yielded highly significant P-values of 8.2016e-
9 and 6.3077e-5 for HMGC2 and AQP8, respectively. Sig-
nificant differences were not observed in infliximab non-
responders nor in placebo responders.
HMGCS2 is a mitochondrial enzyme that catalyzes the
first reaction of ketogenesis, a metabolic pathway that pro-
vides lipid-derived energy for various organs during times
of carbohydrate deprivation, such as fasting. The primary
substrate for this metabolic pathway is acetyl-CoA, which
in turn is derived from -oxidation of short chain fatty
acids such as butyrate, when glucose is limiting. A recent
study showed thatHMGCS2 expression is directly induced
by butyrate in human colonic mucosa (45). Additionally,
this butyrate-dependent upregulation ofHMGCS2 is driven
specifically by butyrate-producing bacterial species colo-
nized in the gut (46,47). A positive correlation between in-
creased butyrate oxidation rates and mucosal healing for
IBD patients has been demonstrated by several groups (48–
50). Our group recently reported that an IBD-associated de-
crease in Roseburia and Phascolarctobacterium may reflect
a decrease in butyrate production (51). Based on these pub-
lished findings and our present results, we posited that acti-
vation of the ketogenesis pathway (by microbiome-derived
butyrate via HMGCS2) is critical for a successful response
to infliximab. Additionally, we predicted that UC patients
bearing an abundant population of butyrate-producing mi-
crobiota are more likely to respond to infliximab than pa-
tients with significantly decreased abundance of these spe-
cific microbial clades. A recent report by Machiels et al.
(39) shows evidence in close support of this hypothesis.
This group reported a significant decrease in the butyrate-
producing bacterial species Roseburia hominis and Faecal-
ibacterium prausnitzii in patients with UC and concluded
that restoration of these bacterial species, or the functional
pathways affected by this dysbiosis, would enhance success-
ful treatment outcomes. In addition to HMGCS2, several
published reports provide evidence in support of AQP8 as
a candidate marker associated with successful treatment re-
sponse to UC (52–54).
Our method enabled us to gain pathway-centric insights
into treatment response where other approaches have failed.
We stratified patients on the basis of our activity measure
and generated a specific hypothesis about a microbiome-
regulated host metabolic pathway that may serve as a
biomarker for matching patient subsets with targeted ther-
apy. The approach presented here resonates with the prin-
ciples of ‘personalized healthcare’ model for patient strati-
fication and stratified medicine (55).
DISCUSSION
In this report, we present a computational method to func-
tionally interpret high-throughput gene expression data and
characterize the levels of activity induced in biological path-
ways. In contrast to other existing FCS methods, MIPA
proposes to evaluate not one but five PCA clustering-based
summary statistics. Systematic sensitivity analysis demon-
strated that our metrics are linearly sensitive to changes in
both magnitude and extent of transcriptional regulation.
Other methods, in contrast, can be too sensitive, less than
moderate, or non-responsive to changes in the same param-
eters.
All pathway-level aggregate statistics are significantly
affected by correlation between member genes. Previous
methods either employ resampling-based approaches that
maintain the correlation structure of the expression data
(56), or attempt to correct for these correlations by estimat-
ing a variance inflation factor directly from the data (57).
However, it is conceivable that correlation between genes
could provide additional information, especially when the
correlation varies substantially across experiments. Such a
change in correlation structure could be indicative of flux
re-routing in a metabolic pathway. However, whether any
of the existing methods have the ability to detect such tran-
scriptional regulation of pathways had not been examined
to date. We have shown that our method can uniquely dis-
criminate between instances when a flux/signal is conserved
versus when it is significantly re-routed within the same
pathway. Our analysis of other methods showed that they
failed to demonstrate such sensitivity.
The final step for any FCS method is assessing the sig-
nificance of the inferred activity measure using one of the
two null hypothesis: (i) a self-contained null hypothesis that
permutes the sample class labels, preserves the correlation
structure between genes and compares the set of genes with
itself or (ii) a competitive null hypothesis that permutes gene
annotations for each set and compares with a same-size set
of genes that are not in the pathway. Most FCS methods
typically choose one of the two methods, although it has
been recommended that self-contained tests be used as an
initial screening to assess the relevance of individual biolog-
ical processes, followed up with a competitive test to distin-
guish the most important biological processes from others
that are less significant (35). Following the recommended
guideline, our framework incorporates a two-stage signifi-
cance analysis pipeline, yielding a robust analysis.
We provide a comprehensive evaluation of every aspect
of our method. We used simulated datasets to estimate the
sensitivity and false positive rates of ourmetrics.We demon-
strated that MIPA outperforms 16 other methods in terms
of Sensitivity, Prioritization (of known targets) and Speci-
ficity. We present an in-depth assessment of robustness and
reproducibility with our method. We believe this analytical
framework can serve as a template for rigorously analyzing
other methods as well.
We selected four transcriptomics datasets that profiled bi-
ological systems at varying scales of complexity and repre-
sented distinct physiological and biological states. Applica-
tion of our computational framework to these case studies
collectively established that our method can (a) identify reg-
ulation in pathways missed by other approaches, (b) iden-
tify gene–gene interactions in genetically engineered mouse
models, (c) identify pathways at the interface of gene–
environment interactions in pathogen-specific host immune
responses and (d) stratify patients and generate specific hy-
pothesis along the gene–environment-therapeutic axis.
The ability to quantify pathway activity for each sam-
ple individually facilitates comprehensive post-hoc analysis
and serves as a robust basis for developing pathway-centric
models and classifiers with machine-learning algorithms.
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The additional capability to identify a subset of driver genes
for any given pathway, which can then be profiled on a tar-
geted platform such as NanoString, opens up the possibil-
ity of developing pathway reporter codesets. The transcrip-
tional profile of these reduced codesets can faithfully repro-
duce the pathway activity signal using our method, and can
be further applied to either classify patient samples or in-
vestigate the functional impact of perturbation or genetic
manipulation studies. We believe our method can not only
be readily applied to other omics datasets independently but
can also be extended to integrate data from diverse modali-
ties by building a coupled annotation set (e.g. pathways an-
notated with genes and metabolites).
Rapid advances in sequencing technologies are ushering
in an era in which generating genome-wide time-series ex-
pression data in a cost-effective manner may be possible.
Irrespective of the kind of data one generates, be it tran-
scriptomics, metabolomics or proteomics, the ultimate end-
point for all functional interpretation tasks is to understand
pathway regulation.We believe that characterizing pathway
dysregulation is central to understanding complex disease
pathogenesis and that therapeutic interventions must be de-
signed with an end-goal of modulating pathway activities.
Our method provides a computational framework to sup-
port such systems biology research, and we present exper-
imental evidence that corroborates its accuracy, specificity
and advantages over other methods.
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